Acute leukaemia types: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 32: | Line 32: | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;" |'''[[CD7]]''' | |colspan="1" style = "font-size:90%; color:black;" |'''[[CD7]]''' | ||
|colspan="1" style = "font-size:80%;"|Similar to TdT, CD7 | |colspan="1" style = "font-size:80%;"|Similar to TdT, although more frequent (20-40%) CD7 yend to be expressed by AML blasts in the more primitive forms. This marker is most consistently a marker of T-lineage (including T-ALL). | ||
|- | |- | ||
|</br> | |</br> |
Revision as of 18:43, 18 July 2023
Expression guide: acute myeloid leukaemia | |||
---|---|---|---|
Markers useful to confirm the primitive phenotype (expressed in both AML and ALL)
| |||
Marker | Comment | ||
CD45 | Expressed by all leukocytes and precursors (100% of cases), but in AML expression is "weak" i.e. significantly less intense than normal T cells, B cells or monocytes. In monocytic AML expression may be stronger. | ||
CD34 | Frequently expressed by AML blast cells (40-80% of cases) - most often in less differentiated forms of AML. However, expression is less frequent and often less intense than in lymphoid leukaemias | ||
TDT | Expressed AML particularly in less differentiated blast cells, often on a sub-population of cells. More typically associated with ALL where expression is generally stronger. | ||
CD7 | Similar to TdT, although more frequent (20-40%) CD7 yend to be expressed by AML blasts in the more primitive forms. This marker is most consistently a marker of T-lineage (including T-ALL). | ||
Markers with very strong lineage specificity in AML | |||
While not expressed by all cases, when detected by flow cytomwtry MPO can be considered to be lineage-defining marker in AML (or establishing myeloid lineage in MPAL). | |||
Marker | Expectation | Comment | |
MPO | A strong lineage marker for AML when detected by flow cytometry (though potentially less so by immunocytochemistry) | ||
Lineage markers in AML that with relatively high speificity | |||
These markers are each expressed by many cases (around 80% for each marker), they have high specificity although abberrent expression in ALL is feequent (overall 10-20% for any individual marker)). | |||
Marker | Expectation | Comment | |
CD117 | One of tne of the first lineage-markers acquired in AML with good relative specificity | ||
CD33 | A good marker for AML that is often less strongly expressed in monocytic forms | ||
CD13 | A good lineage marker for AML aquired a little later, higher than CD13 in monocytic forms | ||
Other markers helpful in detecting myeloid lineage (often in AML subtypes) | |||
These markers have less general value in diagnosis, but can be useful in subtype selection or in cases whwere lineage is ambiguous. | |||
Marker | Expectation | Comment | |
CD10 | Gran | One of tne of the first lineage-markers acquired in AML with good relative specificity | |
CD11b | Gran | One of tne of the first lineage-markers acquired in AML with good relative specificity | |
CD11c | Mono | One of tne of the first lineage-markers acquired in AML with good relative specificity | |
CD14 | Mono | A good marker for AML that is often less strongly expressed in monocytic forms | |
CD64 | Mono | A good lineage marker for AML aquired a little later, higher than CD13 in monocytic forms |